Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 7
2000 13
2001 8
2002 12
2003 14
2004 27
2005 31
2006 20
2007 36
2008 37
2009 47
2010 35
2011 34
2012 43
2013 40
2014 29
2015 23
2016 23
2017 18
2018 13
2019 15
2020 8
2021 7
2022 12
2023 5
2024 9
2025 6
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

529 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.
Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, Grobbee DE, Narkiewicz K, Ojji DB, Poulter NR, Schlaich MP, Oparil S, Spiering W, Williams B, Wright JT Jr, Lakshman P, Uluwattage W, Hay P, Pereira T, Amarasena N, Ranasinghe G, Gianacas C, Shanthakumar M, Liu X, Wang N, Gnanenthiran SR, Whelton PK; GMRx2 Investigators. Rodgers A, et al. Lancet. 2024 Oct 19;404(10462):1536-1546. doi: 10.1016/S0140-6736(24)01744-6. Lancet. 2024. PMID: 39426836 Clinical Trial.
In a 4-week active run-in, existing medications were switched to GMRx2 half dose (telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg). Participants were then randomly allocated (2:1:1:1) to continued GMRx2 half dose or to each possible dual combination of compone …
In a 4-week active run-in, existing medications were switched to GMRx2 half dose (telmisartan 20 mg, amlodipine 2.5 mg, and indapamid …
Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension.
Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, Grobbee D, Narkiewicz K, Ojji DB, Poulter NR, Schlaich MP, Oparil S, Spiering W, Williams B, Wright JT Jr, Gutierez A, Sanni A, Lakshman P, McMullen D, Ranasinghe G, Gianacas C, Shanthakumar M, Liu X, Wang N, Whelton P. Rodgers A, et al. J Am Coll Cardiol. 2024 Dec 10;84(24):2393-2403. doi: 10.1016/j.jacc.2024.08.025. Epub 2024 Aug 31. J Am Coll Cardiol. 2024. PMID: 39217570 Free article. Clinical Trial.
OBJECTIVES: The authors conducted a placebo-controlled trial of a new single-pill combination containing low doses of telmisartan, amlodipine, and indapamide in 2 dose options to assess efficacy and safety. ...Participants were randomized in a 2:2:1 ratio to GMRx2 dose ( …
OBJECTIVES: The authors conducted a placebo-controlled trial of a new single-pill combination containing low doses of telmisartan, am …
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes. ...RESULTS: Mean blood pressure was lower in both the telmisartan group (a 0.9/0.6 mm Hg greater reduction) and …
We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease o …
Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial.
Ojji DB, Salam A, Sani MU, Ogah OS, Schutte AE, Huffman MD, Pant R, Ghosh A, Dhurjati R, Lakshmi JK, Ripiye NR, Orji IA, Kana SA, Abdussalam T, Olawumi AL, Alfa IM, Orimolade OA, Ajayi MO, Rodgers A. Ojji DB, et al. JAMA. 2024 Oct 1;332(13):1070-1079. doi: 10.1001/jama.2024.18080. JAMA. 2024. PMID: 39215620 Free PMC article. Clinical Trial.
The triple-pill protocol involved a novel combination of telmisartan, amlodipine, and indapamide in triple one-quarter, one-half, and standard doses (ie, 10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg), with accelerated up-titration. ...
The triple-pill protocol involved a novel combination of telmisartan, amlodipine, and indapamide in triple one-quarter, one-half, and …
Randomized, double-blinded, controlled clinical trial of the effect of captopril, telmisartan and their combination on systemic inflammation of patients on hemodialysis.
Ordaz-Medina SM, Cueto-Manzano AM, González-Plascencia J, Montañez-Fernández JL, Ordaz-Medina EJ, Martín-Del-Campo F, Cueto-Ramírez AM, Martínez-Martínez P, Cortés-Sanabria L, Rojas-Campos E, Trujillo-Hernández B. Ordaz-Medina SM, et al. Sci Rep. 2022 Oct 20;12(1):17568. doi: 10.1038/s41598-022-22656-5. Sci Rep. 2022. PMID: 36266534 Free PMC article. Clinical Trial.
Patients on HD at least 2 months, with arteriovenous fistula, were randomly allocated to groups: (1) captopril/placebo (N 13); (2) telmisartan/placebo (N 13); (3) captopril + telmisartan (N 12); or (4) placebo/placebo (N 12). ...Monotherapy with captopril or telm …
Patients on HD at least 2 months, with arteriovenous fistula, were randomly allocated to groups: (1) captopril/placebo (N 13); (2) telmis …
[Critically appraised article].
Neumann I, Grassi B. Neumann I, et al. Rev Med Chil. 2012 Jan;140(1):117-20. Epub 2012 Apr 12. Rev Med Chil. 2012. PMID: 22552566 Free article. Clinical Trial. Spanish.
FINDINGS: 784 patients permanently discontinued randomised therapy during the trial because of hypotensive symptoms (406 on combination therapy, 149 on ramipril, and 229 on telmisartan). The number of events for the composite primary outcome was similar for telmisartan …
FINDINGS: 784 patients permanently discontinued randomised therapy during the trial because of hypotensive symptoms (406 on combination ther …
Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial.
Lee SH, Park K, Lee KH, Cho Y, Kim DH, Lim S, Bo Yoon S, Jang JS, Lim HS, Doh JH, Kim DY, Sohn IS, Cheon DY, Bae MH, Kim SH, Lee Y, Ihm SH, Choi RK, Park HJ, Pyun WB, Choi S, Shin J. Lee SH, et al. Clin Ther. 2026 Mar;48(3):240-246. doi: 10.1016/j.clinthera.2026.01.001. Epub 2026 Feb 10. Clin Ther. 2026. PMID: 41672793 Free article. Clinical Trial.
PURPOSE: This randomized, double-blind, multicenter, phase III clinical trial aimed to evaluate the efficacy and safety of telmisartan 20 mg and s-amlodipine 1.25 mg, a fixed-dose combination (Tel/S-Amlo) versus telmisartan 20 mg single therapy or s-amlodipine 1.25 …
PURPOSE: This randomized, double-blind, multicenter, phase III clinical trial aimed to evaluate the efficacy and safety of telmisartan …
Telmisartan vs. other antihypertensives on cardiometabolic and vascular outcomes in diabetic hypertension: A randomised trial.
Gomaz SB, Kaur RJ, Mohandas A, Ambwani S, Charan J, Kumar D, Shukla R, Yadav D. Gomaz SB, et al. Indian J Med Res. 2026 Jan;163(1):41-48. doi: 10.25259/IJMR_1859_2025. Indian J Med Res. 2026. PMID: 41934432 Free PMC article. Clinical Trial.
Results At baseline, the median HOMA-IR values were 4.1 [interquartile range (IQR): 2.2-5.9] in the telmisartan group and 3.9 (IQR: 3.1-5.9) in the comparator group. After 12 weeks, the median HOMA-IR significantly decreased in the telmisartan group to 1.79 (IQR: 1. …
Results At baseline, the median HOMA-IR values were 4.1 [interquartile range (IQR): 2.2-5.9] in the telmisartan group and 3.9 (IQR: 3 …
Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.
Lee CJ, Kang WC, Ihm SH, Sohn IS, Woo JS, Kim JW, Hong SJ, Choi JH, Suh JW, Seo JB, Doh JH, Son JW, Park JH, Lee JH, Hong YJ, Heo JH, Shin J, Kang SM. Lee CJ, et al. J Clin Hypertens (Greenwich). 2024 Mar;26(3):262-273. doi: 10.1111/jch.14778. Epub 2024 Feb 6. J Clin Hypertens (Greenwich). 2024. PMID: 38319595 Free PMC article. Clinical Trial.
This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control and cholesterol-lowering effects and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe versus rosuvastatin and ezetimibe double therapy or telmisartan …
This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control and cholesterol-lowering effects and safety of comb …
Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.
Ahn HS, Ahn JC, Cho JM, Lim KH, Han SH, Cho YK, Kim KH, Hong SJ, Lee CJ, Na JO, Sung KC, Choi K, Kim SY, Kim DH, Lee HC, Ihm SH, Youn JC, Choi JY, Kim SH, Kim KI, Sung JH, Pyun WB, Kim WS, Cho JS, Lee Y, Her SH, Cho EJ, Lee EM, Lee HY, Yoon YW, Lee JH, Kim W, Rhee SJ, Shin J. Ahn HS, et al. J Clin Hypertens (Greenwich). 2026 May;28(5):e70279. doi: 10.1111/jch.70279. J Clin Hypertens (Greenwich). 2026. PMID: 42130156 Free PMC article. Clinical Trial.
However, evidence from randomized controlled trials regarding the efficacy and safety of half-dose telmisartan/amlodipine SPCs remains limited. In this randomized, double-blind, active-controlled phase III trial, patients with essential hypertension [mean sitting systolic …
However, evidence from randomized controlled trials regarding the efficacy and safety of half-dose telmisartan/amlodipine SPCs remain …
529 results